摘要
Sexual dysfunction and prostate cancer are common among older men. Few studies explored the association between these two illnesses. We examined whether sexual function is associated with prostate cancer risk among older men. Among 448 men undergoing prostate biopsy at the Durham Veterans Affairs Hospital, sexual function was ascertained from the Expanded Prostate Cancer Index Composite sexual assessment. We tested the link between sexual function and prostate cancer risk adjusting for multiple demographic and clinical characteristics using logistic regression. Multinomial logistic regression was used to test the associations with risk of low-grade （Gleason 〈6） and high-grade （Gleason 〉7 or 〉4 ＋ 3） disease versus no cancer. Of 448 men, 209 （47%） had a positive biopsy; these men were less likely to be white （43% vs 55%, P=0.013）, had higher prostate-specific antigen （PSA） （6.0 vs 5.4 ng ml-1, P 〈 0.001）, but with lower mean sexual function score （47 vs 54, P = 0.007）. There was no difference in age, BMI, pack years smoked, history of heart disease and/or diabetes. After adjusting for baseline differences, sexual function was linked with a decreased risk of overall prostate cancer risk （OR. 0.91 per lO-point change in sexual function, P= 0.004） and high-grade disease whether defined as Gleason ≥7 （OR： 0.86, P= 0.001） or 〉4 ＋ 3 （OR： 0.85, P= 0.009）. Sexual function was unrelated to low-grade prostate cancer （OR： 0.94, P = 0.13）. Thus, among men undergoing prostate biopsy, higher sexual function was associated with a decreased risk of overall and high-grade prostate cancer. Confirmatory studies are needed.
Sexual dysfunction and prostate cancer are common among older men. Few studies explored the association between these two illnesses. We examined whether sexual function is associated with prostate cancer risk among older men. Among 448 men undergoing prostate biopsy at the Durham Veterans Affairs Hospital, sexual function was ascertained from the Expanded Prostate Cancer Index Composite sexual assessment. We tested the link between sexual function and prostate cancer risk adjusting for multiple demographic and clinical characteristics using logistic regression. Multinomial logistic regression was used to test the associations with risk of low-grade （Gleason 〈6） and high-grade （Gleason 〉7 or 〉4 ＋ 3） disease versus no cancer. Of 448 men, 209 （47%） had a positive biopsy; these men were less likely to be white （43% vs 55%, P=0.013）, had higher prostate-specific antigen （PSA） （6.0 vs 5.4 ng ml-1, P 〈 0.001）, but with lower mean sexual function score （47 vs 54, P = 0.007）. There was no difference in age, BMI, pack years smoked, history of heart disease and/or diabetes. After adjusting for baseline differences, sexual function was linked with a decreased risk of overall prostate cancer risk （OR. 0.91 per lO-point change in sexual function, P= 0.004） and high-grade disease whether defined as Gleason ≥7 （OR： 0.86, P= 0.001） or 〉4 ＋ 3 （OR： 0.85, P= 0.009）. Sexual function was unrelated to low-grade prostate cancer （OR： 0.94, P = 0.13）. Thus, among men undergoing prostate biopsy, higher sexual function was associated with a decreased risk of overall and high-grade prostate cancer. Confirmatory studies are needed.
